Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.

By Hannele Yki-Järvinen. The Lancet Diabetes and Endocrinology, 2014

1,128 citations recorded by the source corpus.

Subfields: Biochemistry, Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/f6c17ed6ac6a26be03fbfc8a2e5ab26bbccc1d2e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Q. Anstee
2. A. Sanyal
3. A. Lonardo
4. Bart Staels
5. G. Targher
6. Z. Younossi
7. Megan H. Bair-Merritt

In Epidemiology

1. Q. Anstee
2. A. Sanyal
3. V. Ratziu
4. Giulio Marchesini
5. S. Harrison
6. A. Lonardo
7. Z. Younossi
8. G. Targher

Citations in the corpus

• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016, background): “However, NASH is also a multisystem disease that could worsen insulin resistance, the metabolic syndrome, and the systemic inflammatory state.(6) Consequently, NASH patients also have an increased rate of cardiovascular events and neoplasia.”
• Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. (2015, background): “Moreover, while most studies cknowledge NAFLD to be a risk factor for T2D [24], the notion that AFLD anticipates the future development of components of the etabolic syndrome other than T2D is far less accepted, although t has been suggested by few authors [23,25,26] mainly based on heir expert opin”